ClinicalTrials.gg
RecruitingNCT06970028Updated Nov 17, 2025

Somatosensory Phenotyping of ADPKD

An observational study in ADPKD and Pain, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
150
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Polycystic Kidney, Autosomal Dominant with a site in Belgium — 3 open to participants now, 7 under way, 2 of them phase 3. Polycystic Kidney, Autosomal Dominant · Belgium.

Started
2025
with 2 others
Observational
5 of 19
1 open now
Registered
18th of 19
by date

Among the 19 studies in Polycystic Kidney, Autosomal Dominant with a site in Belgium, this one is one of 3 that started in 2025, is one of 5 observational ones, and was the 18th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

3 of the 19 studies in Polycystic Kidney, Autosomal Dominant with a site in Belgium are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Polycystic Kidney, Autosomal Dominant with a site in Belgium, or all of them as a file.
02

Study summary

Over 60% of patients with ADPKD suffer from pain, mostly in the abdomen, flank and back, often leading to the diagnosis. It is challenging to manage and cure the pain; approximately 39% of patients are not satisfied with their pain treatment, since the pain prevents them from doing various activities, affecting their quality of life. Pain can be present before enlargement of the kidneys, the source of the pain is often unknown and common analgesics are insufficient to manage the pain or cannot be taken due to renal impairment. By further investigating and characterizing the pain phenotype of the ADPKD population, pain management might be improved and alternative therapeutic approaches might be developed. In this clinical study, pain will be assessed in patients with ADPKD using Quantitative Sensory Testing (QST) on the dominant hand and the lower back, together with four questionnaires regarding pain and quality of life. These results will be compared with the somatosensory profile of matched healthy volunteers.

03

Conditions studied

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with ADPKD from the University Hospitals Leuven will be included in this study. Additionally, healthy volunteers will be included using the registered database of the Center for Clinical Pharmacology (UZ Leuven).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients with ADPKD

  • Subject is ≥ 12 years old.
  • Subject is diagnosed with ADPKD.

Healthy volunteers

  • Subject is ≥ 12 years old.
  • Subject is in good general health, based on medical history and vital signs.
  • Subject is matched to the patient group for age, sex and .

Exclusion criteria

Exclusion Criteria:

Patients with ADPKD

  • Subject has eczema, scleroderma, psoriasis, dermatitis, or any other abnormality on the skin of the dominant hand and/or lower back which, in the investigator's opinion, might interfere with the study assessments.
  • Subject is currently undergoing dialysis, had a kidney transplant or is a user of tolvaptan.
  • Female who is pregnant or breastfeeding.
  • Simultaneous participation in another study which, in the investigator's opinion, might confound the results of the study.
  • Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, and/or consumes ≥ 3 alcoholic consumptions per day.
  • Subject is a regular user of cannabis, any illicit drugs and/or has a history of drug abuse.
  • Subject is unable to refrain from drinking caffeinated beverages (such as coffee, tea, cola,…) 24 hours prior to each study visit.
  • Subject has used concomitant drugs and/or treatments in a period smaller than or equal to 5 half-lives prior to enrollment, that may interfere, in the investigator's opinion, with the study results.
  • Subject has a history of any illness or condition which, in the investigator's opinion, may interfere with safe and optimal participation in the study.

Healthy volunteers

  • Subject has a history of any illness or condition which may affect the normal somatosensory functionality.
  • Subject has eczema, scleroderma, psoriasis, dermatitis, or any other abnormality on the skin of the dominant hand and/or lower back which, in the investigator's opinion, might interfere with the study assessments.
  • Female who is pregnant or breast-feeding.
  • Simultaneous participation in another study which, in the investigator's opinion, might confound the results of the study.
  • Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, and/or consumes ≥ 3 alcoholic consumptions per day.
  • Subject is a regular user of cannabis, any illicit drugs and/or has a history of drug abuse.
  • Subject is unable to refrain from drinking caffeinated beverages (such as coffee, tea, cola,…) 24 hours prior to each study visit.
  • Subject has used concomitant drugs and/or treatments in a period smaller than or equal to 5 half-lives prior to enrollment, that may interfere, in the investigator's opinion, with the study results.
  • Subject has a history of any illness or condition which, in the investigator's opinion, may interfere with safe and optimal participation in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with ADPKD

    Patients with ADPKD will be included (≥ 12 years old). The somatosensory profile will be described using Quantitative Sensory Testing and questionnaires regarding pain and quality of life.

    Other: Quantitative Sensory Testing · Other: Questionnaires regarding pain and quality of life

  • Healthy volunteers

    Healthy volunteers will be included (≥ 12 years old), matched with the patient group based on age, sex and BMI. The somatosensory profile will be described using Quantitative Sensory Testing and the BPI-SF questionnaire.

    Other: Quantitative Sensory Testing

Interventions

  • OtherQuantitative Sensory Testing

    We will perform QST on the dominant hand and lower back.

  • OtherQuestionnaires regarding pain and quality of life

    Questionnaires will be filled out by patients with ADPKD to evaluate pain and quality of life.

06

What researchers measure

Primary outcomes

  1. Somatosensory phenotyping of ADPKD using Quantitative Sensory Testing (QST)

    The somatosensory phenotype of patients with ADPKD will be evaluated using QST on the dominant hand and lower back. These results will be compared with the somatosensory phenotype of matched healthy volunteers.

    Time frame: Interval of ≤ 3 months between screening and study visit

  2. Describing pain in ADPKD using the ADPKD-PDS questionnaire

    (Potential) pain in the last 7 days will be assessed using the ADPKD-PDS questionnaire, which contains 20 questions (1-5 Likert scale) in 7 domains: Dull Pain Severity, Sharp Pain Severity, Discomfort Severity, Overall Pain and Discomfort Severity, Dull Pain Interference, Sharp Pain Interference, and Discomfort Interference. Unit of Measure: Total score per domain

    Time frame: Interval of ≤ 3 months between screening and study visit

  3. Describing neuropathic pain in ADPKD using the DN4 questionnaire

    The DN4 questionnaire will be used to evaluate whether the (potential) pain is neuropathic. The questionnaire consists of 10 yes/no questions, in which a total score of 4/10 or higher is considered indicative of neuropathic pain. Unit of Measure: Total DN4 score (/10)

    Time frame: Interval of ≤ 3 months between screening and study visit

  4. Describing quality of life in ADPKD using the ADPKD-IS questionnaire

    Quality of life will be assessed using the ADPKD-IS questionnaire, which consists of 18 questions (1-5 Likert scale) in 3 domains (physical, emotional, fatigue) and 4 additional elements (guilt, sleep, size/shape of abdomen, urinary frequency/urgency). Unit of Measure: Total score per domain/element

    Time frame: Interval of ≤ 3 months between screening and study visit

  5. Comparing pain between patients with ADPKD and healthy volunteers using the BPI-SF questionnaire

    The BPI-SF questionnaire consists of 9 questions, concerning both the intensity and impact of pain on daily functioning in the last 24 hours. This questionnaire will be conducted in patients with ADPKD and healthy volunteers.

    Time frame: Interval of ≤ 3 months between screening and study visit

Secondary outcomes

  1. Correlation between QST and questionnaires

    A correlation between QST results and results from the questionnaires will be assessed in patients with ADPKD.

    Time frame: Interval of ≤ 3 months between screening and study visit

  2. Differences in somatosensory phenotype depending on the disease stage of ADPKD

    Potential differences in somatosensory phenotype depending on the disease stage of patients with ADPKD (stage 1-5) will be evaluated using statistical analyses.

    Time frame: Interval of ≤ 3 months between screening and study visit

  3. Differences in somatosensory phenotype depending on the sex of patients with ADPKD

    Potential differences in the somatosensory phenotype (QST) of female and male patients with ADPKD will be evaluated using statistical analyses.

    Time frame: Interval of ≤ 3 months between screening and study visit

  4. Differences in pain and quality of life depending on the sex of patients with ADPKD

    Potential differences in pain and quality of life, described using questionnaires, of female and male patients with ADPKD will be evaluated using statistical analyses.

    Time frame: Interval of ≤ 3 months between screening and study visit

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
May 14, 2025
StartActual
Sep 9, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06970028
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Sep 9, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 17, 2025

Study contacts

Flore Van Olmen, MSc
Contact
flore.vanolmen@uzleuven.be
+32 016 34 22 01
Jan de Hoon, MD, PhD, MSc
principal investigator · UZ Leuven

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion